Angiotensin receptor blockers and myocardial infarction - Wikidata - awgldk - TriplyDB

Angiotensin receptor blockers and myocardial infarction

Angiotensin receptor blockers and myocardial infarction

http://www.wikidata.org/entity/Q24559659

about

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice.Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Thymosin β4 promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium.Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection Angiotensin receptor blockers and risk of myocardial infarction: systematic review.Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Emerging drugs for diabetic nephropathy.Therapeutic potential of angiotensin receptor blockers in hypertension.Valsartan in the treatment of heart attack survivors Vascular benefits of angiotensin receptor blockers.Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients.Angiotensin receptor blockers in hypertension. New insights from Japan.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancer.Cardiovascular medications in angiogenesis--how to avoid the sting in the tail.Angiotensin II receptor antagonists in acute coronary syndromes.Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan using RP HPLC The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate.Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed.Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke.Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension.Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves.Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.Angiotensin receptor blockers and endpoint protection.Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document 2007 ESH‐ESC Guidelines for the management of arterial hypertension

P2860

Q24658205-DB9A829C-D3F9-4D25-8C00-10767FE58CAC Q26767278-D1859F0B-B033-4E4A-A016-B0B0C4A33C9B Q30432209-19D7DCA7-8247-40B2-AC9C-77879929E7BC Q33245267-0AAC4416-D5E4-4404-AE94-576FFC735A39 Q33403831-35709B56-BC91-44C1-BA34-A83454C7A805 Q33674848-C274FA28-3ACB-4577-9A3C-7E74A83A8173 Q34068728-4B5E6FF6-F36E-4D8A-9219-A991B68A39A6 Q34081519-F8F573BE-809F-421D-ABC8-E762FD2697EE Q34231611-885196C9-C752-47B7-AF4E-0D5A5E0DEE23 Q34386587-3F631DA7-7A4F-428B-9749-7EA9997189AA Q35539305-90CA4ED7-0E20-4AEB-A112-7FAE26F28ABB Q35808362-89103BEE-FEAD-4D15-BEFA-19956BB8D73B Q36249947-47F7BEF4-B2B3-467D-9109-F0CE6E7A3F47 Q36302833-0B54EF50-F691-460D-BC52-C3BD463856C9 Q36302838-9827DA42-2661-4B6E-B8D6-8FB1C6B8093C Q36491825-5C036B56-E7E7-4C93-9703-B1C32972ABDC Q36744015-CBAA7D3E-DEC5-46EC-8A05-917F477F53FC Q36861584-B242F25E-9987-4609-B5D7-A8ADC4E0CAC2 Q37642900-E7E7CFCD-F2A4-4D80-A3F4-1B8ADC6F3376 Q37691240-100E5EED-FA2B-4537-8C62-AC0E287196F1 Q37827882-47C10790-ED64-42AE-9B9D-5E1C31048777 Q37869264-21DDDA90-C53E-447C-9B5A-98EA0E34F96C Q37879662-F4CCF968-35FC-43C1-9A1B-65DBFAA73F13 Q38001305-3E5DA4C0-72C8-441B-9270-DC67FE54DEB6 Q38167346-0FF76F3E-91F4-4AEA-8D03-52B1B032D6FB Q39643542-B4A9DD05-217B-4344-8E16-DA2A643073EA Q41469746-12D7B424-5725-448A-BF42-AC228444078F Q42123922-03D98831-878C-416C-BFCA-C6F7037A9BD6 Q42758342-A5878977-C09C-48E7-9F7A-1083E084DDE5 Q43060073-7754F41B-7B01-4FB4-B311-BBA05017BA38 Q43060094-19561406-7A84-4858-A9FE-6B31EAF88701 Q43060486-708ED07A-3AB3-4F78-A5BA-099F147CE466 Q43060502-927CD33C-D2A2-4B97-8210-CF9105E949CC Q43811034-E4817FC4-191B-4C24-A4C7-B5F5CA0C0BEC Q46668164-0D8C5A87-1859-4A19-A4CE-E00F5CBAB448 Q46886153-611D4D90-0C28-40D6-A78B-0F17032BCC3C Q51800530-2E5017DE-FBC3-4D29-912F-CE1961864D6B Q53845954-7CD6E919-A797-4EB0-95C3-710BB0C159AE Q56970710-4F6846D3-26AC-4C8C-89D2-1410F6EBA37C Q56970799-93152CEC-5AA6-47E6-BA4E-CE93414FC831

P2860

Angiotensin receptor blockers and myocardial infarction

http://www.wikidata.org/entity/Q24559659

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Angiotensin receptor blockers and myocardial infarction

@ast

Angiotensin receptor blockers and myocardial infarction

@en

Angiotensin receptor blockers and myocardial infarction

@nl

type

label

Angiotensin receptor blockers and myocardial infarction

@ast

Angiotensin receptor blockers and myocardial infarction

@en

Angiotensin receptor blockers and myocardial infarction

@nl

prefLabel

Angiotensin receptor blockers and myocardial infarction

@ast

Angiotensin receptor blockers and myocardial infarction

@en

Angiotensin receptor blockers and myocardial infarction

@nl

P1433

Q24559659-D6EF9DB0-27CC-45B0-8470-3DA5E589D632

P1476

Q24559659-EDE046BF-727E-4E64-B7F0-161D3BF911DA

P2093

Q24559659-134C8A2D-415E-43D3-9DB4-8B41512906D1

Q24559659-559A4D15-CD23-4C4E-A457-6938CDDEB4D9

P2860

Q24559659-1E64803A-5C60-454B-A7D4-CCF3BC8DBFF7

Q24559659-311C375C-C7AE-49CE-B351-500F14345C75

Q24559659-3FF5FAD6-78F3-4326-AF15-8F3A3960A35C

Q24559659-49DB5B9F-AE34-4CF6-9E9C-03DF20434710

Q24559659-5677F52E-4D26-434D-8829-100CA17F908F

Q24559659-5C235418-9F16-4B9D-A6F7-D318E8D37BD7

Q24559659-75D1CE50-200F-41E5-8143-2A614197A9D2

Q24559659-8EDC97DD-753C-4555-AF73-59A88AD56DD5

Q24559659-EEE655AC-6870-4FF9-9B46-1E9508EF479F

Q24559659-F1A3B47D-E668-47F9-80D4-D746DEE093FE

P304

Q24559659-AE1C8B07-E091-42E5-B19B-F01FC31D765E

P31

Q24559659-EE49BCCF-71F7-4E6A-8107-8FCE9687106D

P356

Q24559659-3BC5CBCA-5BA7-4EA2-AD04-C866DB5BFA3D

P407

Q24559659-D1512A03-2014-4707-B1FC-4E40D2FF777E

P433

Q24559659-77D10AE0-206C-4EBE-B10D-4270CB0B4C72

P478

Q24559659-0CC8FDFA-A55F-4CDC-B61C-BBB64A816225

P577

Q24559659-564E4978-EAC3-470A-A41E-958B0CC0784B

P5875

Q24559659-034C9A75-C634-480A-B208-71B6EE10B04B

P698

Q24559659-20DAF264-3B75-4BCF-A51C-8B8480FDA81B

P921

Q24559659-70C31ED0-789E-4E4E-AC11-226FA67EF780

P932

Q24559659-FC19B1E9-AC77-4A72-B647-81376A7DC6C2

P356

BMJ.329.7477.1248

P1433

P1476

Angiotensin receptor blockers and myocardial infarction

@en

P2093

Marty Strauss

http://www.w3.org/2001/XMLSchema#string

Subodh Verma

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

Blood-pressure reduction and cardiovascular risk in HOPE study.

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

P304

1248-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.329.7477.1248

http://www.w3.org/2001/XMLSchema#string

P407

P433

7477

http://www.w3.org/2001/XMLSchema#string

P478

329

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8163592

http://www.w3.org/2001/XMLSchema#string

P698

15564232

http://www.w3.org/2001/XMLSchema#string

P921

P932

534428

http://www.w3.org/2001/XMLSchema#string